Department of Medicine, Division of Cardiology, McMaster University, Hamilton, ON, Canada.
Population Health Research Institute, Hamilton, ON, Canada.
Can J Anaesth. 2021 Nov;68(11):1611-1629. doi: 10.1007/s12630-021-02083-2. Epub 2021 Aug 17.
Cardiogenic shock carries high morbidity and mortality. The purpose of this review was to determine the safety and efficacy of pulmonary artery catheterization (PAC) in adult patients hospitalized with cardiogenic shock.
We performed a systematic review and meta-analysis of observational studies and randomized controlled trials comparing PAC vs no PAC in cardiogenic shock. We searched MEDLINE, EMBASE, Cochrane CENTRAL, and grey literature. We screened articles, abstracted data, and evaluated risk of bias in duplicate. We pooled data using a random-effects model and evaluated the quality of evidence using the GRADE framework. Outcomes of interest were mortality, length of stay, and procedural complications.
We identified 19 eligible observational studies (≥ 2,716,287 patients) and no randomized controlled trials; 14 studies were at high risk of bias (lack of adjustment for prognostic variables and/or co-interventions). When pooling adjusted results, PAC was associated with improved survival to hospital discharge (relative risk [RR], 0.77; 95% confidence interval [CI], 0.64 to 0.91, I = 98%; very low-quality evidence) and at longest available follow-up (RR, 0.72; 95% CI, 0.60 to 0.87; I = 99%; very low-quality evidence). Unadjusted length of stay was 3.5 days longer (95% CI, 1.49 to 5.54; I = 100%; very low-quality evidence) with PAC. Procedural complications were inconsistently reported.
Very low-quality observational evidence suggests PAC use in patients with cardiogenic shock is associated with lower mortality. Overall, these results support consideration of PAC for hemodynamic assessment in cardiogenic shock. Prospective randomized clinical trials are needed to further characterize the role of PAC in this population.
心源性休克具有较高的发病率和死亡率。本综述旨在确定肺动脉导管(PAC)在成人充血性休克患者中的安全性和疗效。
我们对比较 PAC 与充血性休克中无 PAC 的观察性研究和随机对照试验进行了系统评价和荟萃分析。我们检索了 MEDLINE、EMBASE、Cochrane 中心和灰色文献。我们双人筛选文章、提取数据并评估偏倚风险。我们使用随机效应模型汇总数据,并使用 GRADE 框架评估证据质量。主要结果是死亡率、住院时间和程序并发症。
我们确定了 19 项符合条件的观察性研究(≥2,716,287 例患者)和没有随机对照试验;14 项研究存在高偏倚风险(缺乏对预后变量和/或联合干预的调整)。当汇总调整后的结果时,PAC 与提高出院时存活率相关(相对风险 [RR],0.77;95%置信区间 [CI],0.64 至 0.91,I = 98%;极低质量证据),并在最长的可用随访中相关(RR,0.72;95% CI,0.60 至 0.87;I = 99%;极低质量证据)。使用 PAC 后住院时间平均延长 3.5 天(95% CI,1.49 至 5.54;I = 100%;极低质量证据)。程序并发症的报告不一致。
极低质量的观察性证据表明,在心源性休克患者中使用 PAC 与死亡率降低相关。总体而言,这些结果支持在充血性休克中考虑 PAC 进行血流动力学评估。需要前瞻性随机临床试验来进一步确定 PAC 在该人群中的作用。